Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9,035 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Antigen presenting cell-mediated expansion of human umbilical cord blood yields log-scale expansion of natural killer cells with anti-myeloma activity.
Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJ, Decker WK, Li S, Robinson SN, Sekine T, Parmar S, Gribben J, Wang M, Rezvani K, Yvon E, Najjar A, Burks J, Kaur I, Champlin RE, Bollard CM, Shpall EJ. Shah N, et al. PLoS One. 2013 Oct 18;8(10):e76781. doi: 10.1371/journal.pone.0076781. eCollection 2013. PLoS One. 2013. PMID: 24204673 Free PMC article.
NK antibody therapy: KIR-ative intent.
Shah N, Shpall EJ. Shah N, et al. Blood. 2009 Sep 24;114(13):2567-8. doi: 10.1182/blood-2009-07-230904. Blood. 2009. PMID: 19779042 Free article. No abstract available.
Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion.
Xing D, Ramsay AG, Gribben JG, Decker WK, Burks JK, Munsell M, Li S, Robinson SN, Yang H, Steiner D, Shah N, McMannis JD, Champlin RE, Hosing C, Zweidler-McKay PA, Shpall EJ, Bollard CM. Xing D, et al. Among authors: shah n. J Immunother. 2010 Sep;33(7):684-96. doi: 10.1097/CJI.0b013e3181e475e9. J Immunother. 2010. PMID: 20664358 Free PMC article.
Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma.
Yang H, Robinson SN, Nieto Y, Jones RJ, Gocke CD, Lu J, Giralt SA, Jones RB, Decker WK, Xing D, Steiner D, Champlin RE, McMannis JD, Ng J, Thomas MW, Shah N, Andersson BS, Parmar S, Shpall EJ. Yang H, et al. Among authors: shah n. Cancer Res. 2011 Jul 15;71(14):5040-9. doi: 10.1158/0008-5472.CAN-11-0842. Epub 2011 Jun 6. Cancer Res. 2011. PMID: 21646477
Feasibility of autologous hematopoietic stem cell transplant in patients aged ≥70 years with multiple myeloma.
Bashir Q, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Orlowski RZ, Thomas SK, Shah J, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Bashir Q, et al. Among authors: shah j, shah n. Leuk Lymphoma. 2012 Jan;53(1):118-22. doi: 10.3109/10428194.2011.606942. Epub 2011 Aug 24. Leuk Lymphoma. 2012. PMID: 21780997
A randomized phase 2 trial of a preparative regimen of bortezomib, high-dose melphalan, arsenic trioxide, and ascorbic acid.
Sharma M, Khan H, Thall PF, Orlowski RZ, Bassett RL Jr, Shah N, Bashir Q, Parmar S, Wang M, Shah JJ, Hosing CM, Popat UR, Giralt SA, Champlin RE, Qazilbash MH. Sharma M, et al. Among authors: shah n, shah jj. Cancer. 2012 May 1;118(9):2507-15. doi: 10.1002/cncr.26517. Epub 2011 Sep 1. Cancer. 2012. PMID: 21887685 Free PMC article. Clinical Trial.
Predictors of prolonged survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.
Bashir Q, Khan H, Orlowski RZ, Amjad AI, Shah N, Parmar S, Wei W, Rondon G, Weber DM, Wang M, Thomas SK, Shah JJ, Qureshi SR, Dinh YT, Popat U, Anderlini P, Hosing C, Giralt S, Champlin RE, Qazilbash MH. Bashir Q, et al. Among authors: shah n, shah jj. Am J Hematol. 2012 Mar;87(3):272-6. doi: 10.1002/ajh.22273. Epub 2012 Jan 9. Am J Hematol. 2012. PMID: 22231283 Free PMC article.
Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant.
Beitinjaneh AM, Saliba R, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Anderlini P, Dinh Y, Qureshi S, Rondon G, Champlin RE, Giralt SA, Qazilbash MH. Beitinjaneh AM, et al. Among authors: shah n. Leuk Lymphoma. 2012 Aug;53(8):1525-9. doi: 10.3109/10428194.2012.656635. Epub 2012 Mar 1. Leuk Lymphoma. 2012. PMID: 22242817
High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies.
Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. Nieto Y, et al. Among authors: shah n. Biol Blood Marrow Transplant. 2012 Nov;18(11):1677-86. doi: 10.1016/j.bbmt.2012.05.011. Epub 2012 May 27. Biol Blood Marrow Transplant. 2012. PMID: 22643322 Free PMC article.
9,035 results